Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report.

IF 2.8 4区 医学 Q2 ONCOLOGY
Alessia Surgo, Valerio Davì, Maria Paola Ciliberti, Roberta Carbonara, Morena Caliandro, Fiorella Cristina Di Guglielmo, Nicola Sasso, Roberto Calbi, Maria Annunziata Gentile, Tiziana Talienti, Isabella Bruno, Michele Troia, Ilaria Bonaparte, Giuseppe Mario Ludovico, Giammarco Surico, Alba Fiorentino
{"title":"Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report.","authors":"Alessia Surgo, Valerio Davì, Maria Paola Ciliberti, Roberta Carbonara, Morena Caliandro, Fiorella Cristina Di Guglielmo, Nicola Sasso, Roberto Calbi, Maria Annunziata Gentile, Tiziana Talienti, Isabella Bruno, Michele Troia, Ilaria Bonaparte, Giuseppe Mario Ludovico, Giammarco Surico, Alba Fiorentino","doi":"10.3390/curroncol31120598","DOIUrl":null,"url":null,"abstract":"<p><p>A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplatin (75 mg/m<sup>2</sup> every 21 days) and pemetrexed (500 mg/m<sup>2</sup> every 21 days), and ICI with Atezolizumab (1200 mg every 21 days). In July 2022, RT to the lung tumor and mediastinal nodal was performed with a total dose of 45 Gy in 15 fractions. He continued with immunotherapy until December 2022, when a grade 3-4 toxicity from immunotherapy was observed (hypothyroidism, psoriasis, and cystitis). He achieved a complete clinical response to the therapy. To date, the patient is alive, with a complete metabolic response, without treatment at 37 months from diagnosis.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"8118-8126"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11675016/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31120598","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplatin (75 mg/m2 every 21 days) and pemetrexed (500 mg/m2 every 21 days), and ICI with Atezolizumab (1200 mg every 21 days). In July 2022, RT to the lung tumor and mediastinal nodal was performed with a total dose of 45 Gy in 15 fractions. He continued with immunotherapy until December 2022, when a grade 3-4 toxicity from immunotherapy was observed (hypothyroidism, psoriasis, and cystitis). He achieved a complete clinical response to the therapy. To date, the patient is alive, with a complete metabolic response, without treatment at 37 months from diagnosis.

转移性癌基因阴性、pdl1阴性非小细胞肺癌化疗-免疫和放疗后代谢完全缓解1例报告
一位71岁男性前吸烟者于2021年10月因脑和骨转移性腺癌NSCLC来到我科。PDL1、ROS、EGFR、ALK均为阴性。他接受了立体定向放射治疗脑转移。2021年11月,他开始了顺铂(75 mg/m2 / 21天)和培美曲塞(500 mg/m2 / 21天)的化疗(CHT)方案,以及阿特唑单抗(1200 mg/ 21天)的ICI方案。2022年7月,对肺肿瘤及纵隔淋巴结行放射治疗,总剂量为45 Gy,分15个部分。他继续接受免疫治疗,直到2022年12月,当时观察到免疫治疗的3-4级毒性(甲状腺功能减退、牛皮癣和膀胱炎)。他对治疗取得了完全的临床反应。迄今为止,患者存活,在诊断后37个月没有治疗,有完全的代谢反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current oncology
Current oncology ONCOLOGY-
CiteScore
3.30
自引率
7.70%
发文量
664
审稿时长
1 months
期刊介绍: Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信